Liquidia Corporation Common Stock (LQDA)
Liquidia Corporation Common Stock（LQDA）的公开报告公司资料与已保存市场数据，附来源与数据时间。已保存数据并非实时行情。
公司概况
Liquidia Corporation is a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases. The company's current focus spans the development and commercialization of products in pulmonary hypertension and other applications of its proprietary PRINT Technology. PRINT enabled the creation of YUTREPIA (treprostinil) inhalation powder, a drug approved in 2025 for the treatment of PAH. YUTREPIA is currently under development for other indications, including SSc-RP and PH-COPD. The company is also developing L606, an investigational extended-release formulation of treprostinil administered twice daily with a next-generation nebulizer.
公司资料
- 板块
- Health Care
- 行业
- Pharmaceutical Preparations
- 市值
- $2.4B
- 注册国家/地区
- United States
- 公司官网
- www.liquidia.com
- 交易所
- NASDAQ
已保存报价
已保存快照，并非实时行情。使用前请核对行情时间。
- 已报告价格
- $33.0102
- 已报告涨跌幅
- +23.13%
- 已报告成交量
- 21,143,410
- 最新行情时间
空头持仓量
- 已报告空头持仓量
- 12,640,721 股
- 结算日期
- 来源
- Nasdaq
交易所公布的指定结算日空头持仓量，并非实时空头头寸。
近期日线交易日
最近 10 个已保存的日线交易日，截至 。日线 OHLC 与成交量，并非实时数据。
| 日期 | 开盘 | 最高 | 最低 | 收盘 | 成交量 |
|---|---|---|---|---|---|
| 27.04 | 27.40 | 26.13 | 26.81 | 7,653,314 | |
| 29.27 | 30.86 | 27.27 | 27.67 | 4,414,322 | |
| 27.06 | 28.53 | 26.66 | 27.38 | 3,616,981 | |
| 26.34 | 29.35 | 26.34 | 28.02 | 5,259,541 | |
| 25.55 | 27.33 | 24.59 | 26.68 | 6,987,842 | |
| 27.95 | 28.30 | 25.76 | 25.91 | 5,313,684 | |
| 28.07 | 28.48 | 25.92 | 27.64 | 7,759,906 | |
| 26.69 | 29.18 | 26.31 | 28.64 | 8,404,136 | |
| 23.96 | 28.10 | 22.31 | 27.99 | 21,573,270 | |
| 70.54 | 71.93 | 29.86 | 30.26 | 22,953,200 |
研究这家公司
FennEdge 整理 SEC 文件与已报告市场数据。登录后可使用更多研究功能和私人交易信息。
登录后继续